Preparation time
less than 30 mins
Cooking time
30 mins to 1 hour
Serves
Serves 4
Smoked mackerel fishcakes are served with a quick, seasonal chutney and a light salad.
For the gooseberry chutney, put the gooseberries, onion, garlic, mustard and lemon juice in a preserving pan and pour over two-thirds of the vinegar. Add the peppercorns and bring to the boil.
Reduce the heat and simmer for about 10 minutes, stirring occasionally, until thick.
Add the raisins, sugar and the remaining vinegar. Season with a pinch of salt. Stir over a low heat until the sugar is dissolved, then simmer for up to 30 minutes, stirring frequently, until thick and syrupy. Remove from the heat and set aside to cool.
For the smoked fishcakes, heat the oil in a deep-fat fryer to 190C/375F. (CAUTION: hot oil can be dangerous. Do not leave unattended.) Alternatively, heat the oil in a deep, heavy-based saucepan until a breadcrumb sizzles and turns brown when dropped into it.
Mix the mackerel, mashed potato and chilli in a bowl until well combined. Season with salt and freshly ground black pepper and add lime juice, to taste.
Shape the mixture into 2cm/¾in diameter balls.
Sprinkle the flour onto one plate, beat the egg in a bowl, then place the breadcrumbs on another plate.
Dredge each ball in the flour, then dip it in the beaten egg and roll in the breadcrumbs until completely coated.
Carefully lower the fishcakes into the hot oil and fry for 3-4 minutes, or until crisp, golden-brown and completely cooked through. Remove from the pan using a slotted spoon and set aside to drain on kitchen paper. Keep warm until needed.
For the celery and watercress salad, place the celery, leaves and watercress in a bowl.
In a small bowl or jug, whisk the oil, vinegar and honey together. Season with salt and pepper and whisk again.
Just before serving pour the dressing over the salad and mix.
To serve, place a spoonful of chutney on each plate and place the fish cakes on top. Garnish with the celery and watercress salad.


The filtering process would produce an error for a single bimodule. Fixed that.
Filter bimodules with scores lower than the BH multiple testing threshold. But this doesn’t help with scrambled much.
Th new function half_permutation_fdr
estimates CBCE’s false discovery rate across different values of alpha using half-permutation.
The function filter_bimodules
filters bimodules for overlaps.
Allow singleton bimodules (the KISS principle).
Change the output format. result$comms
will be all unqiue communities, result$comms.fil
will be the filtered communities. result$summary
gives a summary.
Brought back the heursitic search!
Allow covariates directly to be passed to our method.
To correct for covariate removal, added a new parameter n.eff. Removal of each covariate, reduces the degrees of freedom and that must be accounted for in the p-value calculations. This doesn’t matter when the sample size is large, but it does make a difference when it is small.
Use conservative multiple testing correction (BY) by default.
Use deterministic starts by default to avoid surpirses
Randomly choose initial sets to starts with.
Parameter to stop extractions from growing very large.
Use local numbering for the extraction index.
- Added a
NEWS.md
file to track changes to the package.


Image maps you create can be any size or shape you like. They can provide any number of speed options for mouseover scrolling. Image maps you create can be any size or shape you like. They can provide any number of speed options for mouseover scrolling. Image maps you create can be any size or shape you like. They can provide any number of speed options for mouseover scrolling. Image maps you create can be any size or shape you like. They can provide any number of speed options for mouseover scrolling. Image maps you create can be any size or shape you like. They can provide any number of speed options for mouseover scrolling. Image maps you create can be any size or shape you like. They can provide any number of speed options for mouseover scrolling.
|
|
Different portions of the scroll images provide different speeds for scrolling.
Code comments included in this document will assist you in setting up the code. Please also refer to online documentation as needed.
This demo uses tables for layout. See other demos for other layout and style options.
Back to index for more demo's and information.


The confirmation link has expired. Please enter your email address below to request a new confirmation link
NOTE: You can change this page.


x
About Me
I'm a designer, developer, and marketer in pursuit of unicorndom. Why? Because unicorns are cool. Right now I think I am about 22% there.
Some unicorns I admire: Dave Morin, Drew Wilson, Amadeus Demarzi, Kyle Bragger, Dustin Curtis, Steven Kovar


The Adventures of Jerry Muskrat
by Thornton W. Burgess
Chapter 6: “Farmer Brown’s Boy Is Puzzled”
Additional Information
- Year Published: 1914
- Language: English
- Country of Origin: United States of America
- Source: Burgess, T.W. (1914). The Adventures of Jerry Muskrat.
-
Readability:
- Flesch–Kincaid Level: 5.5
- Word Count: 654
- Genre: Fantasy
- ✎ Cite This
Downloads
Farmer Brown’s boy was whistling merrily as he tramped down across the Green Meadows. The Merry Little Breezes saw him coming, and they raced over to the Smiling Pool to tell Billy Mink. Farmer Brown’s boy was coming to visit his traps. He was very sure that he would find Billy Mink or Little Joe Otter, or Jerry Muskrat, or perhaps Bobby Coon.
Billy Mink was sitting on top of the Big Rock. He saw the Merry Little Breezes racing across the Green Meadows, and behind them he saw Farmer Brown’s boy. Billy Mink dived head first into the Smiling Pool. Then he swam over to Jerry Muskrat’s house and warned Jerry. Together they hunted up Little Joe Otter, and then the three little scamps in brown hid in the bulrushes, where they could watch Farmer Brown’s boy.
The first place Farmer Brown’s boy visited was Jerry Muskrat’s old log. Very cautiously he peeped over the edge of the bank. The trap was gone!
“Hurrah!” shouted Farmer Brown’s boy. He was very much excited, as he caught hold of the end of the chain, which fastened it to the old log. He was sure that at last he had caught Jerry Muskrat. When he pulled the trap up, it was empty. Between the jaws were a few hairs and a little bit of skin, which Jerry Muskrat had left there when he sprung the trap with his tail.
Farmer Brown’s boy was disappointed. “Well, I’ll get him to-morrow, anyway,” said he to himself. Then he went on to his next trap; it was nowhere to be seen. When he pulled the chain he was so excited that he trembled. The trap did not come up at once. He pulled and pulled, and then suddenly up it came, all covered with mud. In it was one little claw from Little Joe Otter. Very carefully Farmer Brown’s boy set the trap again. If he could have looked over in the bulrushes and have seen Little Joe Otter and Billy Mink and Jerry Muskrat watching him and tickling and laughing, he would not have been so sure that next time he would catch Little Joe Otter.
All around the Smiling Pool and then up and down the Laughing Brook Farmer Brown’s boy tramped, and each trap he found sprung and buried in the mud. He had stopped whistling by this time, and there was a puzzled frown on his freckled face. What did it mean? Could some other boy have found all his traps and played a trick by springing all of them? The more he thought about it, the more puzzled he became. You see, he did not know anything about the busy day the Minks and the Otters and the Muskrats and the Coons had spent the day before.

“Chugarum!” said Grandfather Frog, as he snapped up a foolish green fly. “Much good it will do you to set those traps again!”
Then Grandfather Frog called to Billy Mink and sent him to tell all the other little people of the Smiling Pool and the Laughing Brook that they must hurry and spring all the traps again as they had before.
This time it was easy, because they knew just where the traps were, so all day long they dropped sticks and stones into the traps and once more sprung them. Then they prepared for a grand feast of the good things to eat which Farmer Brown’s boy had left, scattered around the traps.


There are no borrowed books to be displayed!
| Title | Borrowed by | Overdue | |
|---|---|---|---|
| {{book.title}} | {{author.firstName}} {{author.lastName}}{{$last ? '' : ', '}} | {{book.borrowerFirstName}} {{book.borrowerLastName}} [{{book.borrowerUUID.substring(0,2) + ".." + book.borrowerUUID.substring(book.borrowerUUID.length - 2,book.borrowerUUID.length)}}] | {{book.dueDate}} |


What if we want to scroll to a specific item in the viewport? This can be done via scrollToItem option of the Adapter.fix method. This option specifies an item predicate function, and the first item in the Buffer, that satisfies this predicate, will be the item to which the viewport will scroll.
Scrolling is performed via element.scrollIntoView() native DOM Element interface's method. According to its specification, it accepts 1 optional argument which can be a Boolean parameter or special Object parameter (details can be found on MDN). To provide this option, the Adapter.fix method handles another property of its argument object: scrollToItemOpt. The demo shows how to use it.


'I will fight until the end': Last Hong Kong PolyU protesters hold out at campus
HONG KONG: Dozens of protesters stood firm inside a besieged Hong Kong University on Wednesday (Nov 20), as a standoff with police showed no signs of ending.
Protesters have held the Hong Kong Polytechnic University (PolyU) campus since Sunday, wielding Motolov cocktails, bricks and arrows.
A large "SOS" sign was laid out across an open courtyard, apparently intended to be viewed from above.
READ: Options narrow for last Hong Kong campus protesters as arrests take a toll
READ: Dozens of Hong Kong protesters escape campus siege on motorbikes
A 20-year-old protester, who gave his name as Ken, said food and water supplies were running low.
 “Some people want to get out but they cannot. So we left this SOS.”
Protesters said about 50 of them remained after hundreds had fled deteriorating conditions and officials warned that police may fire live rounds.
Around 20 of the holdouts are students of the university, a PolyU official said.
"NEVER GIVE UP"
A 15-year-old armed with a bow and arrow, who identified himself as William, said: "I don't ever give up. Yes, I will fight until the end.
"But ... it's very dangerous, because when you use the bow, the police must shoot you, with some unknown bullets. Maybe real bullets."
READ: Choking and crying, Hong Kong protesters pinned back on campus
Some protesters considered hiding in the maze of campus buildings, as they said a teacher advised them to do.
"I already know where I will hide," a 19-year-old student, who gave his name only as Paul, said as he emerged in a hoodie, shorts and slippers to ask about breakfast in the canteen.
"I have enough food for at least a week and then will see what happens," he said.
Two protesters in full body armour, wielding metal rods, were going to get some sleep in the library after their night shift watching police movements outside.
"We need some energy to get ready for the big fight. Now that there's not many of us left they may want to come in," said a former student named Marc, 26.
"We know this place, it's our home and it is a maze. And we have weapons. We're not going to give up now, it's too late for that," he said.
READ: Anxious families wait outside besieged Hong Kong campus
On Monday, some protesters made daring escapes by sliding down ropes and running to motorcycles waiting to get them away, while others attempted to leave through the sewers.
"It has been a disastrous life for us spending these days in Polytechnic University, because we can't live here. The supply of food, water, electricity is going to run out," said a student named Alesa, who said she had tried twice to escape through the sewer.
"It's in vain," she said. "I'm a bit upset, but overall, I'm peaceful. I think if a generation are destined to be criminals, who is to save the next generation?" she said.
Hong Kong's Chief Executive Carrie Lam called for the protesters’ surrender on Tuesday, adding that those over 18 would face rioting charges, but minors would not be arrested.
Police have arrested more than 1,100 people on charges including rioting and possession of offensive weapons, they said.
MORE: Our coverage of the Hong Kong protests
Follow us on Telegram for the latest on Hong Kong: https://cna.asia/telegram


Notifications Example
Unread
2
Read
24
KBase MAGs
3
User feed
James Jeffryes has been added to cool_kids.
8 days ago
James Jeffryes has been added to cool_kids.
8 days ago
KBase MAGs
James Jeffryes has been added to cool_kids.
8 days ago
James Jeffryes has been added to cool_kids.
8 days ago


{{ctrl.serviceToBind}} has been bound to
{{ctrl.applicationToBind}} successfully.
The binding {{ctrl.binding.metadata.name}} has been created successfully.
The binding operation created the secret
{{ctrl.binding.spec.secretName}}{{ctrl.binding.spec.secretName}}
that you may need to reference in your application.
Its data will be available to your application as environment variables.
Info
The binding secret will only be available to new pods. You will need to redeploy your application.
Error
The binding could not be created.
{{ctrl.error.data.message | upperFirst}}
An error occurred creating the binding.


Design changes everything.
The Future of Phones
Comes in 32, 128, and 256 GB
Most Powerful In The World
Light-Weight and Amazingly Comfortable Plastic Cover Of The Century
You would LOVE to take it where even you go!
A Customizable Phone just for you!
You'd be glad you bought it


Dark Knights Vol VII
Melodic House & Techno, Trance
| # | Track | Artist |
|---|---|---|
| 1 | It’s A Lot (Extended) | Goom Gum |
| 2 | Roped In (Extended Mix) | Gorgon City |
| 3 | Right On (Original Mix) | Space Motion |
| 4 | Perfect Motion (Patrice Bäumel Renaissance Remix) | Sunscreem |
| 5 | To The Moon And Back (Original Mix) | Boris Brejcha, Ginger |
| 6 | My Boy (Meduza Remix) | R Plus, Dido |
| 7 | Piu (Original Mix) | Oliver Schories |
| 8 | Palladion (Original Mix) | Hidden Empire |
| 9 | Midnight (Original Mix) | HOSH, 1979, Jalja |
| 10 | Keep Control (ARTBAT Remix) | Sono |
| 11 | Desire (Original Mix) | Matador |
| 12 | Hold Me To The Light (Tale Of Us Remix) | KASST, Be No Rain |
| 13 | Without You (Extended Mix) | Leftwing Kody, Camden Cox |
| 14 | Elessar (Original Mix) | Moonwalk |
| 15 | Headnoise (Get Hype) (Extended Mix) | Martin Ikin, Dope Earth Alien |
| 16 | Higher State Of Consciousness (Adana Twins Remix Two) | Josh Wink |
| 17 | Power Over Me (MEDUZA Remix - Extended) | Meduza, Dermot Kennedy |
| 18 | Blue Monday (Extended Mix) | Above & Beyond |
| 19 | Universal Nation (Bart Skils Remix) | Push |
| 20 | Dreams (Umek Version) | Quench, Umek |
1:53:08


Guidelines for submitting metadata regarding Covid19 biosamples and their associated cases to sequence repositories like IRIDA, NCBI Bioproject, and GISAID.
| Field | Description | Guidance | Examples | Data Status |
|---|---|---|---|---|
Database Identifiers |
||||
| specimen collector sample ID | The user-defined name for the sample. | Store the collector sample ID. If this number is considered identifiable information, provide an alternative ID. Be sure to store the key that maps between the original and alternative IDs for traceability and follow up if necessary. Every collector sample ID from a single submitter must be unique. It can have any format, but we suggest that you make it concise, unique and consistent within your lab. | prov_rona_99 | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| third party lab service provider name | The name of the third party company or laboratory that provided services. | Store the sample identifier supplied by the third party services provider. | Switch Health | None |
| third party lab sample ID | The identifier assigned to a sample by a third party service provider. | SHK123456 | None | |
| NML submitted specimen primary ID | The primary ID of the specimen submitted thorough the National Microbiology Laboratory (NML) LaSER. | Store the identifier for the specimen submitted through the NML LaSER system. | SR20-12345 | None |
| NML related specimen primary ID | The primary ID of the related specimen previously submitted thorough the National Microbiology Laboratory (NML) LaSER. | Store the primary ID of the related specimen previously submitted thorough LaSER | SR20-12345 | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| IRIDA sample name | The identifier assigned to a sequenced isolate in IRIDA. | Store the IRIDA sample name. The IRIDA sample name will be created by the individual entering data into the IRIDA platform. IRIDA samples may be linked to metadata and sequence data, or just metadata alone. It is recommended that the IRIDA sample name be the same as, or contain, the specimen collector sample ID for better traceability. It is also recommended that the IRIDA sample name mirror the GISAID accession. IRIDA sample names cannot contain slashes. Slashes should be replaced by underscores. See IRIDA documentation for more information regarding special characters (https://irida.corefacility.ca/documentation/user/user/samples/#adding-a-new-sample). | prov_rona_99 | None |
| umbrella bioproject accession | The INSDC accession number assigned to the umbrella BioProject for the Canadian SARS-CoV-2 sequencing effort. | Store the umbrella BioProject accession by selecting it from the picklist in the template. The umbrella BioProject accession will be identical for all CanCOGen submitters. Different provinces will have their own BioProjects, however these BioProjects will be linked under one umbrella BioProject. | PRJNA623807 | None |
| bioproject accession | The INSDC accession number of the BioProject(s) to which the BioSample belongs. | Store the BioProject accession number. BioProjects are an organizing tool that links together raw sequence data, assemblies, and their associated metadata. Each province will be assigned a different bioproject accession number by the National Microbiology Lab. A valid NCBI BioProject accession has prefix PRJN e.g., PRJNA12345, and is created once at the beginning of a new sequencing project. | PRJNA608651 | None |
| biosample accession | The identifier assigned to a BioSample in INSDC archives. | Store the accession returned from the BioSample submission. NCBI BioSamples will have the prefix SAMN. | SAMN14180202 | None |
| SRA accession | The Sequence Read Archive (SRA) identifier linking raw read data, methodological metadata and quality control metrics submitted to the INSDC. | Store the accession assigned to the submitted "run". NCBI-SRA accessions start with SRR. | SRR11177792 | None |
| GenBank accession | The GenBank identifier assigned to the sequence in the INSDC archives. | Store the accession returned from a GenBank submission (viral genome assembly). | MN908947.3 | None |
| GISAID accession | The GISAID accession number assigned to the sequence. | Store the accession returned from the GISAID submission. | EPI_ISL_436489 | None |
Sample collection and processing |
||||
| sample collected by | The name of the agency that collected the original sample. | The name of the sample collector should be written out in full, (with minor exceptions) and be consistent across multple submissions e.g. Public Health Agency of Canada, Public Health Ontario, BC Centre for Disease Control. The sample collector specified is at the discretion of the data provider (i.e. may be hospital, provincial public health lab, or other). | BC Centre for Disease Control | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| sample collector contact email | The email address of the contact responsible for follow-up regarding the sample. | The email address can represent a specific individual or lab e.g<EMAIL_ADDRESS>or<EMAIL_ADDRESS>|<EMAIL_ADDRESS>| None |
| sample collector contact address | The mailing address of the agency submitting the sample. | The mailing address should be in the format: Street number and name, City, Province/Territory, Postal Code, Country | 655 Lab St, Vancouver, British Columbia, V5N 2A2, Canada | None |
| sequence submitted by | The name of the agency that generated the sequence. | The name of the agency should be written out in full, (with minor exceptions) and be consistent across multple submissions. If submitting specimens rather than sequencing data, please put the "National Microbiology Laboratory (NML)". | Public Health Ontario (PHO) | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| sequence submitter contact email | The email address of the contact responsible for follow-up regarding the sequence. | The email address can represent a specific individual or lab e.g<EMAIL_ADDRESS>or<EMAIL_ADDRESS>|<EMAIL_ADDRESS>| None |
| sequence submitter contact address | The mailing address of the agency submitting the sequence. | The mailing address should be in the format: Street number and name, City, Province/Territory, Postal Code, Country | 123 Sunnybrooke St, Toronto, Ontario, M4P 1L6, Canada | None |
| sample collection date | The date on which the sample was collected. | Sample collection date is critical for surveillance and many types of analyses. Required granularity includes year, month and day. If this date is considered identifiable information, it is acceptable to add "jitter" by adding or subtracting a calendar day (acceptable by GISAID). Alternatively, ”received date” may be used as a substitute. The date should be provided in ISO 8601 standard format "YYYY-MM-DD". | 2020-03-16 | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| sample collection date precision | The precision to which the "sample collection date" was provided. | Provide the precision of granularity to the "day", "month", or "year" for the date provided in the "sample collection date" field. The "sample collection date" will be truncated to the precision specified upon export; "day" for "YYYY-MM-DD", "month" for "YYYY-MM", or "year" for "YYYY". | year | None |
| sample received date | The date on which the sample was received. | ISO 8601 standard "YYYY-MM-DD". | 2020-03-20 | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| geo_loc_name (country) | The country where the sample was collected. | Provide the country name from the controlled vocabulary provided. | Canada | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| geo_loc_name (state/province/territory) | The province/territory where the sample was collected. | Provide the province/territory name from the controlled vocabulary provided. | Saskatchewan | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| geo_loc_name (city) | The city where the sample was collected. | Provide the city name. Use this look-up service to identify the standardized term: https://www.ebi.ac.uk/ols/ontologies/gaz | Medicine Hat | None |
| organism | Taxonomic name of the organism. | Use "Severe acute respiratory syndrome coronavirus 2". This value is provided in the template. | Severe acute respiratory syndrome coronavirus 2 | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| isolate | Identifier of the specific isolate. | Provide the GISAID virus name, which should be written in the format “hCov-19/CANADA/xxxxx/2020”. | hCov-19/CANADA/prov_rona_99/2020 | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| purpose of sampling | The reason that the sample was collected. | The reason a sample was collected may provide information about potential biases in sampling strategy. Provide the purpose of sampling from the picklist in the template. Most likely, the sample was collected for Diagnostic testing. The reason why a sample was originally collected may differ from the reason why it was selected for sequencing, which should be indicated in the "purpose of sequencing" field. | Diagnostic testing | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| purpose of sampling details | The description of why the sample was collected, providing specific details. | Provide an expanded description of why the sample was collected using free text. The description may include the importance of the sample for a particular public health investigation/surveillance activity/research question. If details are not available, provide a null value. | The sample was collected to investigate the prevalence of variants associated with mink-to-human transmission in Canada. | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| NML submitted specimen type | The type of specimen submitted to the National Microbiology Laboratory (NML) for testing. | This information is required for upload through the CNPHI LaSER system. Select the specimen type from the pick list provided. If sequence data is being submitted rather than a specimen for testing, select “Not Applicable”. | swab | [''] |
| NML related specimen relationship type | The relationship of the related specimen to the previous National Microbiology Laboratory (NML) submission. | Provide the specimen type of the original sample submitted from the pick list provided, so that additional specimen testing can be tracked in the system. | Follow-up | None |
| anatomical material | A substance obtained from an anatomical part of an organism e.g. tissue, blood. | Provide a descriptor if an anatomical material was sampled. Use the picklist provided in the template. If a desired term is missing from the picklist, contact<EMAIL_ADDRESS>If not applicable, do not leave blank. Choose a null value. | Blood | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| anatomical part | An anatomical part of an organism e.g. oropharynx. | Provide a descriptor if an anatomical part was sampled. Use the picklist provided in the template. If a desired term is missing from the picklist, contact<EMAIL_ADDRESS>If not applicable, do not leave blank. Choose a null value. | Nasopharynx (NP) | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| body product | A substance excreted/secreted from an organism e.g. feces, urine, sweat. | Provide a descriptor if a body product was sampled. Use the picklist provided in the template. If a desired term is missing from the picklist, contact<EMAIL_ADDRESS>If not applicable, do not leave blank. Choose a null value. | Feces | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| environmental material | A substance obtained from the natural or man-made environment e.g. soil, water, sewage. | Provide a descriptor if an environmental material was sampled. Use the picklist provided in the template. If a desired term is missing from the picklist, contact<EMAIL_ADDRESS>If not applicable, do not leave blank. Choose a null value. | Face mask | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| environmental site | An environmental location may describe a site in the natural or built environment e.g. contact surface, metal can, hospital, wet market, bat cave. | Provide a descriptor if an environmental site was sampled. Use the picklist provided in the template. If a desired term is missing from the picklist, contact<EMAIL_ADDRESS>If not applicable, do not leave blank. Choose a null value. | Production Facility | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| collection device | The instrument or container used to collect the sample e.g. swab. | Provide a descriptor if a device was used for sampling. Use the picklist provided in the template. If a desired term is missing from the picklist, contact<EMAIL_ADDRESS>If not applicable, do not leave blank. Choose a null value. | Swab | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| collection method | The process used to collect the sample e.g. phlebotamy, necropsy. | Provide a descriptor if a collection method was used for sampling. Use the picklist provided in the template. If a desired term is missing from the picklist, contact<EMAIL_ADDRESS>If not applicable, do not leave blank. Choose a null value. | Bronchoalveolar lavage (BAL) | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| collection protocol | The name and version of a particular protocol used for sampling. | Free text. | BCRonaSamplingProtocol v. 1.2 | None |
| specimen processing | Any processing applied to the sample during or after receiving the sample. | Critical for interpreting data. Select all the applicable processes from the pick list. If virus was passaged, include information in "lab host", "passage number", and "passage method" fields. If none of the processes in the pick list apply, put "not applicable". | Virus passage | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| lab host | Name and description of the laboratory host used to propagate the source organism or material from which the sample was obtained. | Type of cell line used for propagation. Provide the name of the cell line using the picklist in the template. If not passaged, put "not applicable". | Vero E6 cell line | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| passage number | Number of passages. | Provide number of known passages. If not passaged, put "not applicable" | 3 | ['Not Applicable'] |
| passage method | Description of how organism was passaged. | Free text. Provide a very short description (<10 words). If not passaged, put "not applicable". | 0.25% trypsin + 0.02% EDTA | ['Not Applicable'] |
| biomaterial extracted | The biomaterial extracted from samples for the purpose of sequencing. | Provide the biomaterial extracted from the picklist in the template. | RNA (total) | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
Host Information |
||||
| host (common name) | The commonly used name of the host. | Common name or scientific name are required if there was a host. Both can be provided, if known. Use terms from the pick lists in the template. Common name e.g. human, bat. If the sample was environmental, put "not applicable. | Human | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| host (scientific name) | The taxonomic, or scientific name of the host. | Common name or scientific name are required if there was a host. Both can be provided, if known. Use terms from the pick lists in the template. Scientific name e.g. Homo sapiens, If the sample was environmental, put "not applicable | Homo sapiens | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| host health state | Health status of the host at the time of sample collection. | If known, select a descriptor from the pick list provided in the template. | Symptomatic | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| host health status details | Further details pertaining to the health or disease status of the host at time of collection. | If known, select a descriptor from the pick list provided in the template. | Hospitalized (ICU) | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| host health outcome | Disease outcome in the host. | If known, select a descriptor from the pick list provided in the template. | Recovered | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| host disease | The name of the disease experienced by the host. | Select "COVID-19" from the pick list provided in the template. | COVID-19 | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| host age | Age of host at the time of sampling. | Enter the age of the host in years. If not available, provide a null value. If there is not host, put "Not Applicable". | 79 | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| host age unit | The unit used to measure the host age, in either months or years. | Indicate whether the host age is in months or years. Age indicated in months will be binned to the 0 - 9 year age bin. | years | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| host age bin | Age of host at the time of sampling, expressed as an age group. | Select the corresponding host age bin from the pick list provided in the template. If not available, provide a null value. | 60 - 69 | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| host gender | The gender of the host at the time of sample collection. | Select the corresponding host gender from the pick list provided in the template. If not available, provide a null value. If there is no host, put "Not Applicable". | male | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| host residence geo_loc name (country) | The country of residence of the host. | Select the country name from pick list provided in the template. | United Kingdom | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| host residence geo_loc name (state/province/territory) | The state/province/territory of residence of the host. | Select the province/territory name from pick list provided in the template. | Quebec | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| host subject ID | A unique identifier by which each host can be referred to e.g. #131 | Provide the host identifier. Should be a unique, user-defined identifier. | BCxy123 | None |
| symptom onset date | The date on which the symptoms began or were first noted. | ISO 8601 standard "YYYY-MM-DD". | 2020-03-16 | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| signs and symptoms | A perceived change in function or sensation, (loss, disturbance or appearance) indicative of a disease, reported by a patient or clinician. | Select all of the symptoms experienced by the host from the pick list. | Chills (sudden cold sensation); Cough; Fever | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| pre-existing conditions and risk factors | Patient pre-existing conditions and risk factors. |
Select all of the pre-existing conditions and risk factors experienced by the host from the pick list. If the desired term is missing, contact the curation team. | Asthma; Pregnancy; Smoking | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| complications | Patient medical complications that are believed to have occurred as a result of host disease. | Select all of the complications experienced by the host from the pick list. If the desired term is missing, contact the curation team. | Acute Respiratory Failure; Coma; Septicemia | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
Host vaccination information |
||||
| host vaccination status | The vaccination status of the host (fully vaccinated, partially vaccinated, or not vaccinated). | Select the vaccination status of the host from the pick list. | Fully Vaccinated | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| vaccine name | The name of the vaccine. | Free text. Provide the name of the vaccine. | Pfizer-BioNTech COVID-19 vaccine | None |
| number of vaccine doses received | The number of doses of the vaccine recived by the host. | Record how many doses of the vaccine the host has received. | 2 | None |
| first dose vaccination date | The date the host was first vaccinated. | Provide the vaccination date in ISO 8601 standard format "YYYY-MM-DD". | 2021-02-26 | None |
| last dose vaccination date | The date the host received their last dose of vaccine. | Provide the date that the last dose of the vaccine was administered. Provide the last dose vaccination date in ISO 8601 standard format "YYYY-MM-DD". | 2021-04-09 | None |
Host exposure information |
||||
| location of exposure geo_loc name (country) | The country where the host was likely exposed to the causative agent of the illness. | Select the country name from pick list provided in the template. | Canada | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| destination of most recent travel (city) | The name of the city that was the destination of most recent travel. | Provide the name of the city that the host travelled to. Use this look-up service to identify the standardized term: https://www.ebi.ac.uk/ols/ontologies/gaz | New York City | None |
| destination of most recent travel (state/province/territory) | The name of the province that was the destination of most recent travel. | Provide the name of the state/province/territory that the host travelled to. Use this look-up service to identify the standardized term: https://www.ebi.ac.uk/ols/ontologies/gaz | California | None |
| destination of most recent travel (country) | The name of the country that was the destination of most recent travel. | Provide the name of the country that the host travelled to. Use this look-up service to identify the standardized term: https://www.ebi.ac.uk/ols/ontologies/gaz | United Kingdom | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| most recent travel departure date | The date of a person's most recent departure from their primary residence (at that time) on a journey to one or more other locations. | Provide the travel departure date. | 2020-03-16 | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| most recent travel return date | The date of a person's most recent return to some residence from a journey originating at that residence. | Provide the travel return date. | 2020-04-26 | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| travel history | Travel history in last six months. | Specify the countries (and more granular locations if known, separated by a comma) travelled in the last six months; can include multiple travels. Separate multiple travel events with a semi-colon. List most recent travel first. | Canada, Vancouver; USA, Seattle; Italy, Milan | None |
| exposure event | Event leading to exposure. | Select an exposure event from the pick list provided in the template. If the desired term is missing, contact the curation team. | Convention | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| exposure contact level | The exposure transmission contact type. | Select direct or indirect exposure from the pick-list. | Direct | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| host role | The role of the host in relation to the exposure setting. | Select the host's personal role(s) from the pick list provided in the template. If the desired term is missing, contact the curation team. | Patient | None |
| exposure setting | The setting leading to exposure. | Select the host exposure setting(s) from the pick list provided in the template. If a desired term is missing, contact the curation team. | Healthcare Setting | None |
| exposure details | Additional host exposure information. | Free text description of the exposure. | Host role - Other: Bus Driver | None |
Host reinfection information |
||||
| prior SARS-CoV-2 infection | Whether there was prior SARS-CoV-2 infection. | Ik known, provide infromation about whether the individual had a previous SARS-CoV-2 infection. Select a value from the pick list. | Yes | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| prior SARS-CoV-2 infection isolate | The identifier of the isolate found in the prior SARS-CoV-2 infection. | Provide the isolate name of the most recent prior infection. Structure the "isolate" name to be ICTV/INSDC compliant in the following format: "SARS-CoV-2/host/country/sampleID/date". | SARS-CoV-2/human/USA/CA-CDPH-001/2020 | None |
| prior SARS-CoV-2 infection date | The date of diagnosis of the prior SARS-CoV-2 infection. | Provide the date that the most recent prior infection was diagnosed. Provide the prior SARS-CoV-2 infection date in ISO 8601 standard format "YYYY-MM-DD". | 2021-01-23 | None |
| prior SARS-CoV-2 antiviral treatment | Whether there was prior SARS-CoV-2 treatment with an antiviral agent. | If known, provide infromation about whether the individual had a previous SARS-CoV-2 antiviral treatment. Select a value from the pick list. | No prior antiviral treatment | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| prior SARS-CoV-2 antiviral treatment agent | The name of the antiviral treatment agent administered during the prior SARS-CoV-2 infection. | Provide the name of the antiviral treatment agent administered during the most recent prior infection. If no treatment was administered, put "No treatment". If multiple antiviral agents were administered, list them all separated by commas. | Remdesivir | None |
| prior SARS-CoV-2 antiviral treatment date | The date treatment was first administered during the prior SARS-CoV-2 infection. | Provide the date that the antiviral treatment agent was first administered during the most recenrt prior infection. Provide the prior SARS-CoV-2 treatment date in ISO 8601 standard format "YYYY-MM-DD". | 2021-01-28 | None |
Sequencing |
||||
| purpose of sequencing | The reason that the sample was sequenced. | The reason why a sample was originally collected may differ from the reason why it was selected for sequencing. The reason a sample was sequenced may provide information about potential biases in sequencing strategy. Provide the purpose of sequencing from the picklist in the template. The reason for sample collection should be indicated in the "purpose of sampling" field. | Baseline surveillance (random sampling) | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| purpose of sequencing details | The description of why the sample was sequenced providing specific details. | Provide an expanded description of why the sample was sequenced using free text. The description may include the importance of the sequences for a particular public health investigation/surveillance activity/research question. Suggested standardized descriotions include: Screened for S gene target failure (S dropout), Screened for mink variants, Screened for B.1.1.7 variant, Screened for B.1.135 variant, Screened for P.1 variant, Screened due to travel history, Screened due to close contact with infected individual, Assessing public health control measures, Determining early introductions and spread, Investigating airline-related exposures, Investigating temporary foreign worker, Investigating remote regions, Investigating health care workers, Investigating schools/universities, Investigating reinfection. | Screened for S gene target failure (S dropout) | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| sequencing date | The date the sample was sequenced. | ISO 8601 standard "YYYY-MM-DD". | 2020-06-22 | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| library ID | The user-specified identifier for the library prepared for sequencing. | The library name should be unique, and can be an autogenerated ID from your LIMS, or modification of the isolate ID. | XYZ_123345 | None |
| amplicon size | The length of the amplicon generated by PCR amplification. | Provide the amplicon size, including the units. | 300bp | None |
| library preparation kit | The name of the DNA library preparation kit used to generate the library being sequenced. | Provide the name of the library preparation kit used. | Nextera XT | None |
| flow cell barcode | The barcode of the flow cell used for sequencing. | Provide the barcode of the flow cell used for sequencing the sample. | FAB06069 | None |
| sequencing instrument | The model of the sequencing instrument used. | Select a sequencing instrument from the picklist provided in the template. | MinIon | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| sequencing protocol name | The name and version number of the sequencing protocol used. | Provide the name and version of the sequencing protocol e.g. 1D_DNA_MinION | https://www.protocols.io/view/covid-19-artic-v3-illumina-library-construction-an-bibtkann | None |
| sequencing protocol | The protocol used to generate the sequence. | Provide a free text description of the methods and materials used to generate the sequence. Suggested text, fill in information where indicated.: "Viral sequencing was performed following a tiling amplicon strategy using the |
Genomes were generated through amplicon sequencing of 1200 bp amplicons with Freed schema primers. Libraries were created using Illumina DNA Prep kits, and sequence data was produced using Miseq Micro v2 (500 cycles) sequencing kits. | None |
| sequencing kit number | The manufacturer's kit number. | Alphanumeric value. | AB456XYZ789 | None |
| amplicon pcr primer scheme | The specifications of the primers (primer sequences, binding positions, fragment size generated etc) used to generate the amplicons to be sequenced. | Provide the name and version of the primer scheme used to generate the amplicons for sequencing. | https://github.com/joshquick/artic-ncov2019/blob/master/primer_schemes/nCoV-2019/V3/nCoV-2019.tsv | None |
Bioinformatics and QC metrics |
||||
| raw sequence data processing method | The names of the software and version number used for raw data processing such as removing barcodes, adapter trimming, filtering etc. | Provide the software name followed by the version e.g. Trimmomatic v. 0.38, Porechop v. 0.2.3 | Porechop 0.2.3 | None |
| dehosting method | The method used to remove host reads from the pathogen sequence. | Provide the name and version number of the software used to remove host reads. | Nanostripper | None |
| consensus sequence name | The name of the consensus sequence. | Provide the name and version number of the consensus sequence. | ncov123assembly3 | None |
| consensus sequence filename | The name of the consensus sequence file. | Provide the name and version number of the consensus sequence FASTA file. | ncov123assembly.fasta | None |
| consensus sequence filepath | The filepath of the consesnsus sequence file. | Provide the filepath of the consensus sequence FASTA file. | /User/Documents/RespLab/Data/ncov123assembly.fasta | None |
| consensus sequence software name | The name of software used to generate the consensus sequence. | Provide the name of the software used to generate the consensus sequence. | Ivar | None |
| consensus sequence software version | The version of the software used to generate the consensus sequence. | Provide the version of the software used to generate the consensus sequence. | 1.3 | None |
| breadth of coverage value | The percentage of the reference genome covered by the sequenced data, to a prescribed depth. | Provide value as a percent. | 95% | None |
| depth of coverage value | The average number of reads representing a given nucleotide in the reconstructed sequence. | Provide value as a fold of coverage. | 400x | None |
| depth of coverage threshold | The threshold used as a cut-off for the depth of coverage. | Provide the threshold fold coverage. | 100x | None |
| r1 fastq filename | The user-specified filename of the r1 FASTQ file. | Provide the r1 FASTQ filename. | ABC123_S1_L001_R1_001.fastq.gz | None |
| r2 fastq filename | The user-specified filename of the r2 FASTQ file. | Provide the r2 FASTQ filename. | ABC123_S1_L001_R2_001.fastq.gz | None |
| r1 fastq filepath | The location of the r1 FASTQ file within a user's file system. | Provide the filepath for the r1 FASTQ file. This information aids in data management. | /User/Documents/RespLab/Data/ABC123_S1_L001_R1_001.fastq.gz | None |
| r2 fastq filepath | The location of the r2 FASTQ file within a user's file system. | Provide the filepath for the r2 FASTQ file. This information aids in data management. | /User/Documents/RespLab/Data/ABC123_S1_L001_R2_001.fastq.gz | None |
| fast5 filename | The user-specified filename of the FAST5 file. | Provide the FAST5 filename. | rona123assembly.fast5 | None |
| fast5 filepath | The location of the FAST5 file within a user's file system. | Provide the filepath for the FAST5 file. This information aids in data management. | /User/Documents/RespLab/Data/rona123assembly.fast5 | None |
| number of base pairs sequenced | The number of total base pairs generated by the sequencing process. | Provide a numerical value (no need to include units). | 387566 | None |
| consensus genome length | Size of the reconstructed genome described as the number of base pairs. | Provide a numerical value (no need to include units). | 38677 | None |
| Ns per 100 kbp | The number of N symbols present in the consensus fasta sequence, per 100kbp of sequence. | Provide a numerical value (no need to include units). | 330 | None |
| reference genome accession | A persistent, unique identifier of a genome database entry. | Provide the accession number of the reference genome. | NC_045512.2 | None |
| bioinformatics protocol | The name and version number of the bioinformatics protocol used. | Further details regarding the methods used to process raw data, and/or generate assemblies, and/or generate consensus sequences can be provided in an SOP or protocol. Provide the name and version number of the protocol. | https://www.protocols.io/groups/cphln-sarscov2-sequencing-consortium/members | None |
Lineage and Variant information |
||||
| lineage/clade name | The name of the lineage or clade. | Provide the Pangolin or Nextstrain lineage/clade name. | B.1.1.7 | None |
| lineage/clade analysis software name | The name of the software used to determine the lineage/clade. | Provide the name of the software used to determine the lineage/clade. | Pangolin | None |
| lineage/clade analysis software version | The version of the software used to determine the lineage/clade. | Provide the version of the software used ot determine the lineage/clade. | 2.1.10 | None |
| variant designation | The variant classification of the lineage/clade i.e. variant, variant of concern. | If the lineage/clade is considered a Variant of Concern, select Variant of Concern from the pick list. If the lineage/clade contains mutations of concern (mutations that increase transmission, clincal severity, or other epidemiological fa ctors) but it not a global Variant of Concern, select Variant. If the lineage/clade does not contain mutations of concern, leave blank. | Variant of Concern | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| variant evidence | The evidence used to make the variant determination. | Select whether the sample was screened using RT-qPCR or by sequencing from the pick list. | RT-qPCR | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| variant evidence details | Details about the evidence used to make the variant determination. | Provide the assay and list the set of lineage-defining mutations used to make the variant determination. If there are mutations of interest/concern observed in addition to lineage-defining mutations, describe those here. | Lineage-defining mutations: ORF1ab (K1655N), Spike (K417N, E484K, N501Y, D614G, A701V), N (T205I), E (P71L). | None |
Pathogen diagnostic testing |
||||
| gene name 1 | The name of the gene used in the diagnostic RT-PCR test. | Provide the full name of the gene used in the test. The gene symbol (short form of gene name) can also be provided. Standardized gene names and symbols can be found in the Gene Ontology using this look-up service: https://bit.ly/2Sq1LbI | E gene (orf4) | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| diagnostic pcr protocol 1 | The name and version number of the protocol used for diagnostic marker amplification. | The name and version number of the protocol used for carrying out a diagnostic PCR test. This information can be compared to sequence data for evaluation of performance and quality control. | EGenePCRTest 2 | None |
| diagnostic pcr Ct value 1 | The Ct value result from a diagnostic SARS-CoV-2 RT-PCR test. | Provide the CT value of the sample from the diagnostic RT-PCR test. | 21 | None |
| gene name 2 | The name of the gene used in the diagnostic RT-PCR test. | Provide the full name of another gene used in an RT-PCR test. The gene symbol (short form of gene name) can also be provided. Standardized gene names and symbols can be found in the Gene Ontology using this look-up service: https://bit.ly/2Sq1LbI | RdRp gene (nsp12) | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| diagnostic pcr protocol 2 | The name and version number of the protocol used for diagnostic marker amplification. | The name and version number of the protocol used for carrying out a second diagnostic PCR test. This information can be compared to sequence data for evaluation of performance and quality control. | RdRpGenePCRTest 3 | None |
| diagnostic pcr Ct value 2 | The Ct value result from a diagnostic SARS-CoV-2 RT-PCR test. | Provide the CT value of the sample from the second diagnostic RT-PCR test. | 36 | None |
| gene name 3 | The name of the gene used in the diagnostic RT-PCR test. | Provide the full name of another gene used in an RT-PCR test. The gene symbol (short form of gene name) can also be provided. Standardized gene names and symbols can be found in the Gene Ontology using this look-up service: https://bit.ly/2Sq1LbI | RdRp gene (nsp12) | ['Not Applicable', 'Missing', 'Not Collected', 'Not Provided', 'Restricted Access'] |
| diagnostic pcr protocol 3 | The name and version number of the protocol used for diagnostic marker amplification. | The name and version number of the protocol used for carrying out a second diagnostic PCR test. This information can be compared to sequence data for evaluation of performance and quality control. | RdRpGenePCRTest 3 | None |
| diagnostic pcr Ct value 3 | The Ct value result from a diagnostic SARS-CoV-2 RT-PCR test. | Provide the CT value of the sample from the second diagnostic RT-PCR test. | 30 | None |
Contributor acknowledgement |
||||
| authors | Names of individuals contributing to the processes of sample collection, sequence generation, analysis, and data submission. | Include the first and last names of all individuals that should be attributed, separated by a comma. | Tejinder Singh, Fei Hu, Joe Blogs | None |
| DataHarmonizer provenance | The DataHarmonizer software version provenance. | The current software version information will be automatically generated in this field after the user utilizes the "validate" function. This information will be generated regardless as to whether the row is valid of not. | DataHarmonizer provenance: v0.13.21 | None |


RT @cczona: Dear everybody,
Join @rubytogether to support sustainable funding for Ruby core infrastructure OSS projects. Thanks! https://t.…
11/19/2015, 4:09:57 PM
Favs: 0
Retweets: 0
link--- layout: tweet ---
RT @cczona: Dear everybody,
Join @rubytogether to support sustainable funding for Ruby core infrastructure OSS projects. Thanks! https://t.…
11/19/2015, 4:09:57 PM
Favs: 0
Retweets: 0
link


Enable Watchpoints
All
Read Only
Write/Freeze Only
None
Log Level
None
Debug
Trace
Max Watchpoints
3
Save


| Path: | README.rdoc |
| Last Update: | Sun Jan 11 06:06:32 +0100 2009 |
ruby gem to use an imap server as a file storage device
imapstore -c put -r -d
imapstore -c snipplet -s
-x
-i
Usage: imapstore -c
imapstore -h
email<EMAIL_ADDRESS>password: password store_tag: IMAPSTORE imap_server: imap.gmail.com imap_port: 993
store_tag is the tag used in the message subject to distinguish imapstore created messages from any other messages in the store.
# First make sure you have the latest version of gem
gem update —system
# add githum gem repository if you haven’t done so
gem sources -a gems.github.com
install gem
sudo gem install imapstore
# Create sample config at ~/.imapstore/config.yml
imapstore -c setup
# Get help
imapstore -h
(The MIT License)
Copyright © 2009 Joan Marc Carbo Arnau
Permission is hereby granted, free of charge, to any person obtaining a copy of this software and associated documentation files (the ‘Software’), to deal in the Software without restriction, including without limitation the rights to use, copy, modify, merge, publish, distribute, sublicense, and/or sell copies of the Software, and to permit persons to whom the Software is furnished to do so, subject to the following conditions:
The above copyright notice and this permission notice shall be included in all copies or substantial portions of the Software.
 IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM, OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE SOFTWARE.


Davis Cup final: Spain beat Canada with wins for Rafael Nadal & Roberto Bautista Agut
Rafael Nadal clinched an emotional Davis Cup victory for Spain over Canada when he beat Denis Shapovalov in front of a jubilant home crowd in Madrid.
His 6-3 7-6 (9-7) win sealed the title, with Roberto Bautista Agut returning to the team three days after his father's death to put the hosts 1-0 up.
Bautista Agut was in tears after beating 19-year-old Felix Auger-Aliassime 7-6 (7-3) 6-3 in the opener.
Nadal's win gave Spain an unassailable 2-0 lead and a sixth Davis Cup title.
The world number one has won all eight of his rubbers this week to help Spain to a first title since 2011 and ensure local fans were celebrating at the end of the inaugural edition of the competition's revamped version.
"When you have this moment it is difficult to describe with words - so many feelings, so many emotions you have never felt," Spain captain Sergi Bruguera told Eurosport.
"Unbelievable. Imagine Roberto yesterday was in the funeral of his father, now he is here giving everything - the mentality, the spirit, giving everything for his team.
"Rafa, he is out of this world, I don't know if he is an alien or what. Not one day we went to sleep before 3am this week."
The new format has featured 18 teams playing in a week-long event in the Spanish capital, with a round-robin group stage followed by knockout rounds. Under the old system, teams played home and away ties through the year.
'I could not be happier' - Nadal caps successful year with team joy
Rafael Nadal had not lost a Davis Cup singles match since 2004 and it was always going to be a tough task for Shapovalov to send the tie to a deciding doubles rubber.
Nadal, who this year won the French Open and US Open to take his total to 19 Grand Slam titles, dominated the first set before the 20-year-old Shapovalov got himself back into the match to force a second-set tie-break.
The youngster saved two match points with blistering back-to-back winners and fashioned a set point of his own, but finally succumbed when he netted a forehand.
Nadal dropped to the ground before being mobbed by his team-mates. When he finally got to his feet, he held aloft Bautista Agut in a tight embrace as the cheers rang out.
"An amazing week, a lot of things we went through - the father of Roberto passed away... a lot of things happened," Nadal said.
"I could not be happier. It has been an unforgettable moment in this amazing stadium; we can't thank the crowd enough. Our team spirit prevails."
Bautista Agut puts aside grief to deliver for Spain
While Nadal's victory settled the title, it was Bautista Agut's performance so soon after his bereavement that heightened the emotions.
Bautista Agut went home on Thursday after his father was taken ill. The Spanish federation later announced the player's dad had died.
But the world number nine returned to Madrid to watch his team-mates beat Great Britain in the semi-finals on Saturday before being recalled for the final.
The 31-year-old, whose mother died last year, pointed to the sky after claiming victory when Auger-Aliassime went wide on the first of three match points.
He hugged his captain Sergi Bruguera before leaping into the arms of his delighted team-mates in the stands.
"It was very special feeling on the court and I just could go out to try my best, give my best," he told Eurosport.
"I am very happy I could win the first point for Spain."
Auger-Aliassime was playing his first match at the revamped tournament this week after an ankle injury, with Canada reaching their first final by using just the same two players in all of their singles and doubles matches - Shapovalov and Vasek Pospisil.
Inaugural event ends on a high
While the new format - the brainchild of Barcelona footballer Gerard Pique - experienced some teething problems this week, the event drew to a close on a high, partly helped by home success.
There had been empty seats at some ties during the week but at Sunday's final there was a packed and noisy arena, where Spain's King Felipe VI was in attendance and singer Shakira - the partner of Pique - performed before the tie started.
Scheduling issues had meant there were some late-night/early-morning finishes but Nadal showed no sign of fatigue as he put in another convincing performance that underlined why he was named most valuable player of the tournament.
His Spanish team will pocket 2.1m euros (£1.8m) and can look forward to next year where Madrid will once again host the event.
Analysis
BBC tennis correspondent Russell Fuller
Rafael Nadal was Spain's standout player - producing eight wins out of eight at a stage of the year when his body usually rebels at the length of the season.
And Roberto Bautista Agut's presence, let alone victory, was awe-inspiring. As understated as ever, he played with poise and fortitude just three days after the death of his father.
Spain benefited from home advantage, but proved themselves the best team. They may boast the world number one, but all five members of their squad played at least one match.
Next year we hope to see more partisan fans, and fewer late finishes.
And, in future, wouldn't it be wonderful to see an expanded World Cup of tennis, featuring both men and women, and played at a more suitable time of the year?
Compromise and collaboration between tennis' varied vested interests is urgently required.


- Created an application prototype of the hospital pathfinding kiosk application with a weekly release cycle in an 8-person team
- The final prototype was ranked first in the Best Feature (in tie) and second in the Best Application (in tie) among 6 teams
- Trained the scrum master to run scrum meetings and the product owner to organize user stories in sprint and product backlogs
- Initiated feature prioritization, coordinated sprint review meetings and consolidated documentation
- Pitched the application prototype to the Brigham and Women’s Hospital administrative team
- Designed UI flow based on analysis of qualitative user data and supervised the UI development process
- Designed, programmed, deployed and tested a service request using Java and JavaFX
- Programmed a real-time functional near-infrared spectroscopy (fNIRS) data collection tool using Java’s multithreading and refined the UI using PyQt in collaboration
- Facilitated the lab with running brain data experiments and performed statistical analysis on collected brain data for the fNIRS research project funded by the National Science Foundation
- Streamlined the experiment data collection and computation pipeline for lab researchers
- Led a team of 4 students, outlined project timeline, and wrote spec documents based on interviews with 9 stakeholders
- Ideated, designed, evaluated, and refined 3 prototypes of increasing complexity through iterative design
- Implemented data parsing, visualization in React, HTML, CSS and Python with RESTful API
- Improved the brain data analysis efficiency and reduced the learning curve for less tech-savvy students in the HCI Lab. Full report here: bit.ly/3sCzU88
- Created a user-friendly roomavailability dashboard to enhance students’ user experience with online on-campus room booking services while collaborating with 3 students
- Maintained a consistent database allowing students to login, schedule or delete booking and email confirmation using Node.js, Express and LowDB
I have been a long-time enthusiast of user-centered designs. My passion lies in discovering and fulfilling underlying user demands to drive better designs, thus creating unique solutions.
Throughout my undergraduate studies at Worcester Polytechnic Institute, my belief in user experience became more and more deeply rooted.
I believe that I will be able to substantiate user-friendly designs using modern technology, or programming, and make them more accessible to all human beings.


Talks
Invited Talks
-
On the Logical Shadow of the Explicit Constructions, Oberwolfach workshop, Mathematical Logic: Proof Theory, Constructive Mathematics, November 2020. Slides
-
Intuitionistic Implications: On the Logics of Spacetime, Second World Logic Day, January 2020. Slides
-
Stones for Bread: A Classical Reading of Intuitionism, Annual Symposium of Iranian Association for Logic, 2020. Slides
-
On the Existence of the Sequent-style Proof Systems, Workshop on Admissible Rule and Unification III, Prague, May 2019. Slides
-
Computational Flows in Arithmetic, Workshop on Bounded Arithmetic, Prague, November 2017. Slides
Contributed Talks
-
Feasible Visser-Harrop property for intuitionistic modal logics, Logic Colloquium 2021. Slides
-
Generalized Heyting Algebras and Duality, BLAST 2021. Slides
-
The BHK Interpretation: looking through Godel’s classical lens, Logic Colloquium 2019. Slides
-
Witnessing Games in Generalized Bounded Arithmetic, LCC 2019. Slides
-
Predicative Implications: A Topological Approach, TACL 2019. Slides
-
Proof Mining in Bounded Arithmetic, The Proof, Computation and Complexity workshop, Types, Sets and Constructions, Trimester Program, Hausdorff Research Institute for Mathematics, Bonn, July 2018. Slides
-
Mining the Surface: Proof Mining in the Bounded World, The Proofs and Computation workshop, Types, Sets and Constructions, Trimester Program, Hausdorff Research Institute for Mathematics, Bonn, July 2018. Slides
-
General Proof Theory, First Annual Symposium of Iranian Association for Logic, Tehran, Iran, May 2013.
Some Seminar Talks
-
On the Existence of the Sequent-style Proof Systems, Groningen, 2021. Slides
-
Intuitionistic Implications: On the Logics of Spacetime, Utrecht, 2020. Slides
-
Steenen voor Brood: A Classical Interpretation of the Intuitionistic Logic, TULIPS, Utrecht University, 2019.
-
Predicative Exponentials: A Topological Approach, Types, Sets and Constructions Trimester Program, Hausdorff Research Institute for Mathematics, Bonn, July 2018.
-
The BHK interpretation: looking through Godel’s classical lens, Types, Sets and Constructions Trimester Program, Hausdorff Research Institute for Mathematics, Bonn, May 2018.
-
Computational Flows in Arithmetic, Swansea University, UK, November 2017. Slides
-
Geometric Modality and Weak Exponentials, University of Nottingham, November 2017.
-
Feasible Interpolation for Frege and Extended Frege, Steklov Institute of Mathematics, Saint Petersburg, June 2016.
-
An Introduction to Bounded Arithmetic, Charles University, Prague, November 2015.
-
Disjoint NP Pairs and Propositional Proof Complexity, Logic Seminar, Institute of Mathematics, Academy of Sciences, Prague, June 2015.
-
Constructive Feasible Arithmetic, Institute of Mathematics, Academy of Sciences, Prague, June 2014.


Stats: 5'11', 180lbs, healthy body as far as heart and liver goes.
I noticed after my night with K and Meth that there were no entries on it so i decided to change that. I've previously used Coke, oxy, MDMA, and Zolpidem (ambien.) This was my first night trying either K or meth so here we go.
I arrived at my friends place for the evening of dosing. We started smoking some meth around 12AM, was going very well. I found it to be quite like cocaine, but thats me. After it was said and done for the first part of the evening prob took like 10ish hits on it. The effects set in in about 8 minutes slowly peaking around the 2 hour mark id say. At this point we were having a good time. It was kind of like having a lot of energy but not wanting to waste it running a marathon. Wanting to just let it be as it is. Make sense? As far as the complete rush it didnt have the 'ton of bricks' high that MDMA has (which i would rate a 10 on high factor). Meth would be about a 6-7. As with cocaine and other euphoricesque speed rush chems, i was a chatter box. Inhibitions were down and I was telling stuff I have really only told one person before. Still though, it was great, i felt liberated.
So then came the ketamine (K).
About 2 hours into it, now 2AM, we snorted up a dose of K. Im not sure of the dose, didnt ask, they thought they knew whatd be right and i trusted them. Im pretty sure it was a standard dose around 30mg maybe? So the K set in within 5 minutes. Basically, I can describe it as being led up a wonderfull hill by meth, then the scene miraculously changing to a roller coaster and K taking me down the first hill though not a super coaster, more like a top notch middle-school coaster. Its not really a rush like a coaster, just an analogy for pushing me over the top.
 Please Please PLEASE, just as precaution, even if you arent planning on sexxing it up, take condoms just incase because it did make me not care about that kind of stuff. I did take one so I was okay, however even if i wouldnt have brought one, I wouldnt of stopped the sex. So, probably with either drug, dose prepared for the what-ifs.
I started to come down around 4:30AMish so thats a good 4 hour high, which is pretty much what I expected. Took a shower, felt great. Not as good as an MDMA shower. I think you are seeing a pattern here, its not awesome as MDMA but still damn good.
Another suggestion, I didnt sweat near as much as on MDMA (well i wasnt dancing at a club, so id prob sweat the same had i been dancing) but still sipped a glass of water an hour. As a footnote to that, I found that K or meth or both inhibited my bladder warnings of fullness a little. So Id try peeing every 1hr or so even if I didn't have to. I didnt feel like i had to just now, but i did. a lot.
It is now 6AM as I type this experience up and im still tingly and coming down. It seems to have a similar after glow to MDMA so i also expect a crash tomorrow afternoon. Im not going to sleep because I have work early, so another addition, doesnt make sleeping the easiest thing to do. I do also notice a bit of light-headed spinning/slight loss of balance when i close my eyes. No visuals or anything from the K, maybe in higher dose though.
[edit after proofread] Also, now around 6:10AM...wait thats not much time passage from 6AM. Ok, another addition is id say during the peaking, time goes by faster, afterwards time seems to slow down.  Very pleasant though, nothing irritating.[end edit]
More suggestions, take gum to keep you from clinching or chewing on your tongue. Although not as prominent during the peaking, as the clenching is with MDMA, while i am coming down right now, im chewing up a storm.
I cant think of much else.  I took half a viagra and had it up for about 45min but it did go away and I didnt reach my 'happy ending.' No regrets though. The high was worth it.
Just a wrap up:
1-CONDOMS even if I dont plan on having sex.
2-Drink water/Pee regularly
3-This combination really worked well for me and would make a great club drug combo.
Play safe everyone! See ya next time
Experience Reports are the writings and opinions of the individual authors who submit them.
Some of the activities described are dangerous and/or illegal and none are recommended by Erowid.


Design for Performance & Accessibility
View the Project on GitHub jenstrickland/design4performance-a11y
When do you think about performance and accessibility?
Many teams optimize performance and add accessibility accommodations in the development phase — after stakeholder sign-off. At this point, the dev team is on the hook for design decisions which may not optimally balance performance and aesthetics, nor consider the experience for users of assistive technology.
This talk describes a design process prioritizing performance and accessibility from the beginning of your project, using:
Straight up content - for use without keyboard navigation
Marcy Sutton documented how performance issues are often nightmares for accessibility, Accessibility and Performance.
Lara Hogan wrote a book, Designing for Performance.
Tim Kadlec produces a podcast for everyone dedicated to making websites faster, The Path to Performance.
Performance Tooling Today is a collection of tools and resources to improve workflow and site performance.
John Foliot of Deque is my helpful accessibility guru.
Other accessibility services: Knowbility, WebAIM, Simply Accessible, The Paciello Group